ArticleTranslational andrology and urology2019

Commentary: 2-year follow up of pembrolizumab as second-line therapy for advanced urothelial cancer ("KEYNOTE 045").

Mayer FishmanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.